hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06324526 id: 070324QL briefTitle: Obesity and Health-related Quality of Life in Patients Receiving Bariatric Surgery in the UK overallStatus: COMPLETED date: 2017-06-01 date: 2022-11-23 date: 2022-11-23 date: 2024-03-22 date: 2024-03-25 name: Imperial College London class: OTHER name: University of Oxford briefSummary: United Kingdom National Bariatric Surgery Registry (NBSR) records between 1st June 2017 and 23rd November 2022 were used to identify people undergoing primary bariatric (weight-loss) surgery. People undergoing primary bariatric (weight-loss) surgery with one baseline and at least one follow-up visit within one year from surgery were included. Statistical models were used to estimate the relationship between quality of life as assessed by a questionnaire and body mass index at baseline and over time. conditions: Quality of Life conditions: Obesity, Morbid conditions: Bariatric Surgery Candidate studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 2160 type: ACTUAL measure: EQ-5D (EuroQol Five Dimension) measure: BMI sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Surgery and Cancer, Imperial College London city: London zip: W2 1NY country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06324513 id: Med-CDED briefTitle: Evaluation of the Efficacy and Tolerability of the Mediterranean Diet Pattern in the Exclusion Diet for Patients With Crohn's Disease. overallStatus: RECRUITING date: 2023-07-27 date: 2025-07-27 date: 2025-10-27 date: 2024-03-22 date: 2024-03-22 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: The proposed study aims to assess the efficacy and tolerability of adapting the CDED to the Mediterranean diet pattern, without compromising its key principles, namely the exclusion of ultra-processed foods with potential pro-inflammatory effects on the intestines. The decision to modify the CDED according to the characteristics of the Mediterranean diet pattern and to evaluate the potential of this modified version of the exclusion diet for Crohn's disease in terms of efficacy and tolerability are the main objectives of this study.
Furthermore, to date, there are no comprehensive multi-omic investigations integrating dietary data with microbiome, metabolome, and transcriptome profiles that can demonstrate the effect of the CDED at "omic" levels. A very recent study on pediatric patients shows interesting results regarding differential profiles of fecal metabolites after administration of CDE or NEE in different weeks of therapy. conditions: Crohn Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 120 type: ESTIMATED name: Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) name: Crohn's disease exclusion diet (CDED) measure: Clinical response to the first phase of diet measure: Clinical remission rate measure: Adherence rate to the Med-CDED diet and comparison to the original CDED both in pediatric and adult cohort measure: Clinical remission rate in adult patients at the end of phase I of diet measure: Transmural response of the thickness of the intestinal loops both in pediatric and adult cohort measure: Assessment of the reduction or normalization of inflammation markers both in pediatric and adult cohort measure: Assessment of clinical remission rate at the end of Phase II of the Med-CDED diet and comparision with the original CDED both in pediatric and adult cohort measure: Assessment of clinical remission rate at the end of Phase III of the Med-CDED diet and comparision with the original CDED both in pediatric and adult cohort measure: Endoscopic response rate obtained at 6 months both in pediatric and adult cohort measure: Assessment of the modification of the intestinal microbiota composition (trough alpha and beta diversity) at the end of the various phases of the Med-CDED and comparison with the original CDED both in pediatric and adult cohort measure: Assessment of the metabolome profiles at the end of the various phases of the Med-CDED and comparison with the original CDED both in pediatric and adult cohort measure: Assessment of the trascriptome profiles at the end of the various phases of the Med-CDED and comparison with the original CDED both in pediatric and adult cohort measure: Ability to maintain a healthy and balanced diet and patient satisfaction with the treatment both in pediatric and adult cohortreceived sex: ALL minimumAge: 4 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Firenze country: Italy name: Paolo Lionetti role: CONTACT email: paolo.lionetti@meyer.it lat: 43.77925 lon: 11.24626 facility: Ospedali Riuniti Villa Sofia-Cervello status: RECRUITING city: Palermo country: Italy name: Ambrogio Orlando role: CONTACT email: ambrogiorlando@gmail.com lat: 38.13205 lon: 13.33561 facility: Università La Sapienza di Roma status: RECRUITING city: Roma country: Italy name: Salvatore Oliva role: CONTACT email: salvatore.oliva@uniroma1.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06324500 id: ASC-US briefTitle: Prognostic Role of Bowel Ultrasound Scan in Children Affected by Acute Severe Colitis overallStatus: RECRUITING date: 2020-03-02 date: 2025-03-02 date: 2025-05-02 date: 2024-03-22 date: 2024-03-22 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: ASC is a life-threatening medical emergency. The lack of a timely intervention has shown to be associated with a mortality rate higher than 20% in adults, whereas a prompt targeted therapy has displayed a decrease of the aforementioned rate to 1%. Therefore, the identification of predictors of poor outcome trough an objective tool may provide crucial help to individualize the timing of second line treatment initiation. At the state of the art, PUCAI represents the only validated tool to appraise the risk of first-line treatment failure and there is a lack of objective methods with a prognostic value in ASC.
BUS has proven to be a reliable tool in assessing disease activity in children with UC and it has also shown statistically significant correlation with endoscopic features of disease activity. Given the literature suggesting a role for BUS in severe UC and the results from our retrospective study we aim to validate our findings trough a prospective assessment of the potential prognostic role of BUS in ASC. conditions: Acute Severe Colitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: Colonic wall thickness of BUS (bowel ultrasound) parameter to predict the failure of first line treatment measure: Color and power Doppler vascularization of BUS (bowel ultrasound) parameter to predict the failure of first line treatment measure: Mesenteric lymph nodes BUS (bowel ultrasound) parameter measure: evaluation of the prognostic value of the ultrasound parameters sex: ALL minimumAge: 1 Year maximumAge: 17 Years stdAges: CHILD facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Florence state: Firenze zip: 50139 country: Italy name: Paolo Lionetti role: CONTACT email: paolo.lionetti@meyer.it lat: 43.77925 lon: 11.24626 facility: Ospedale Maggiore status: RECRUITING city: Bologna country: Italy name: Patrizia Alvisi role: CONTACT email: Patrizia.alvisi@ausl.bologna.it lat: 44.49381 lon: 11.33875 facility: IRCCS Materno Infantile Burlo Garofolo status: RECRUITING city: Trieste country: Italy name: Matteo Bramuzzo role: CONTACT email: matteo.bramuzzo@burlo.trieste.it lat: 45.64953 lon: 13.77679 facility: CMED Centro Médico-Quirúrgico de Enfermedades Digestivas status: RECRUITING city: Madrid country: Spain name: Marta Velasco Rodriguez- Belvis role: CONTACT email: martavrb@gmail.com lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06324487 id: E-10840098-772.02-7487 briefTitle: A New Application in Subacromial Impingement Syndrome overallStatus: ACTIVE_NOT_RECRUITING date: 2023-09-01 date: 2024-04-01 date: 2024-06-01 date: 2024-03-22 date: 2024-03-22 name: Medipol University class: OTHER briefSummary: Individuals diagnosed with Subacromial Impingement Syndrome by a physical therapist based on MRI results and examination findings will be included in the study. 40 people will be randomly divided into blood flow restrictive exercise (BFRT) and structured exercise program (SEP) groups, 20 people in each group. Participants will receive two evaluations: before starting treatment and immediately after 4 weeks of treatment. Pain, shoulder ROM, shoulder functional level, quality of life, shoulder muscle strength, grip strength, and sleep quality evaluation will be performed. The treatment program will be 5 days a week for a total of 4 weeks. The treatment will be individualized by calculating the appropriate resistance loads for the exercise program. All participants will undergo progressive exercises in sessions conducted by a physiotherapist. conditions: Subacromial Impingement Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Progressive Exercises name: Blood Flow Restriction Therapy measure: Pain İntensity measure: Shoulder ROM measure: Quality of Life Assessment measure: Sleep Quality Assessment measure: Shoulder Functional Level Assessment measure: Shoulder Muscle Strength Assessment measure: Grip Strength Assessment sex: ALL minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medipol University city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06324474 id: HA treatment of periodontitis briefTitle: Clinical and Immunological Evaluation of HA in Treatment of Periodontitis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12-12 date: 2024-12-12 date: 2024-03-22 date: 2024-03-22 name: Sana'a University class: OTHER briefSummary: To evaluate the immunological effectiveness of Hyaluronic acid as adjunction treatment to scaling and root planning and scaling and root planning alone.
Comparison between clinical measurement before and after treatment. Evaluate the level of IGF-1 in treated site as immunological marker if periodontal regeneration. conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Hyaluronic acid name: scaling and root planning measure: Changes in Plaque Index measure: Changes in Gingival Index measure: Changes in Papillary Bleeding Index. measure: Periodontal Probing Depth measure: Clinical attachment loss measure: Changes in IGF-1 sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Sana'a university city: Sana'a country: Yemen lat: 15.35472 lon: 44.20667 hasResults: False
nctId: NCT06324461 id: GLUMINS briefTitle: GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery acronym: GLUMINS overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2026-12-31 date: 2027-12-31 date: 2024-03-22 date: 2024-03-22 name: The University of Hong Kong class: OTHER briefSummary: This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 4 days prior to surgery or receive routine care.
Semaglutide (Ozempic; Novo Nordisk, Denmark) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery. conditions: Myocardial Injury studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Open-labelled, superiority randomized controlled trial primaryPurpose: PREVENTION masking: NONE count: 372 type: ESTIMATED name: Semaglutide 0.25mg subcutaneous injection measure: Proportion of patients with MINS measure: Proportion of patients with composite of non-fatal MINS, non-fatal stroke or cardiovascular mortality measure: Proportion of patients with MINS who do not fulfill the 4th universal definition of myocardial infarction measure: Proportion of patients with myocardial infarction according to the 4th universal definition of myocardial infarction measure: Proportion of patients with ischemic stroke measure: Proportion of patients with cardiovascular death measure: Proportion of patients with all-cause mortality measure: Mean days alive and out of hospital measure: Clinically important atrial fibrillation measure: Clinically significant hypoglycaemia measure: Mean peak troponin T concentration measure: Mean area under curve of troponin T concentration measure: Proportion of patients with coronary revascularization measure: Proportion of patients who require readmission for cardiovascular conditions measure: Proportion of patients with non-fatal cardiac arrest measure: Proportion of patients who require hospitalization for heart failure measure: Proportion of patients who develop pulmonary embolism and/or deep vein thrombosis measure: Proportion of patients with International Society on Thrombosis and Haemostasis (ISTH) major bleeding measure: Proportion of patients with bleeding independently associated with mortality following noncardiac surgery (BIMS) measure: Proportion of patients with infection or sepsis measure: Proportion of patients with acute renal failure fulfilling Kidney Disease Improving Global Outcomes (KDIGO) criteria measure: Proportion of patients with acute renal failure requiring dialysis measure: Proportion of patients requiring amputation measure: Mean length of stay measure: Mean length of intensive care unit stay measure: Mean days alive without need for intensive care support sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Queen Mary Hospital city: Hong Kong state: Hong Kong SAR country: China lat: 22.39407 lon: 114.13737 hasResults: False
nctId: NCT06324448 id: PD-tDCS-RCT briefTitle: Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD overallStatus: RECRUITING date: 2024-02-15 date: 2025-02-01 date: 2025-02-28 date: 2024-03-22 date: 2024-03-26 name: Seoul National University Hospital class: OTHER briefSummary: The purpose of this study is to investigate the efficacy and safety of self-administered transcranial direct current stimulation to improve the single- and dual-task gait in patients with Parkinson's disease. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A randomized controlled trial primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Transcranial direct current stimulation measure: Timed-up and go test (sec) measure: Timed-up and go test under dual-task condition (sec) measure: Dual-task effect (%) in Timed-up and go test measure: modified Attention Allocation Index (mAAI) in Timed-up and go test measure: Gait parameters measure: Single-leg stance test measure: Stroop test measure: Trail making test measure: New freezing of gait questionnaire (NFoGQ) measure: Geriatric depression scale (GDS)-short form measure: Timed-up and go test (sec) measure: Timed-up and go test under dual-task condition (sec) measure: Dual-task effect (%) in Timed-up and go test measure: modified Attention Allocation Index (mAAI) in Timed-up and go test measure: Gait parameters measure: Single-leg stance test measure: Stroop test measure: Trail making test measure: New freezing of gait questionnaire (NFoGQ) measure: Geriatric depression scale (GDS)-short form sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital status: RECRUITING city: Seoul zip: 03080 country: Korea, Republic of name: Han Gil Seo, MD role: CONTACT phone: 82-2-2072-1659 email: hgseo80@gmail.com lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06324435 id: 2000037439 id: U54AA027989 type: NIH link: https://reporter.nih.gov/quickSearch/U54AA027989 briefTitle: Apremilast for Alcohol Use Disorder Treatment in Women and Men overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-02-28 date: 2025-02-28 date: 2024-03-22 date: 2024-03-22 name: Yale University class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) name: Office of Research on Women's Health (ORWH) briefSummary: For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD). conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 10 type: ESTIMATED name: Apremilast measure: Alcohol Consumption sex: ALL minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06324422 id: Fatigue & Parkinson's disease briefTitle: Exercise as Treatment of Fatigue in Parkinson´s Disease overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-01 date: 2026-12-01 date: 2024-03-22 date: 2024-03-22 name: University of Aarhus class: OTHER briefSummary: The primary goal of this study is to test whether 12 weeks of high-intensity aerobic exercise can treat fatigue in Parkinsons disease (PD).
It is hypothesized that persons with PD receiving 12 weeks of high-intensity aerobic exercise will show superior effects on perceived fatigue (i.e., clinical relevant reductions) when compared to the PD control group (primary hypothesis), and that these effects are sustained after 12-weeks of follow up (secondary hypothesis). conditions: Parkinson's Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled multi-site trial with follow-up primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 94 type: ESTIMATED name: Aerobic exercise intervention name: Resistance exercise intervention measure: Change in Modified Fatigue Impact Scale measure: Change in Fatigue Severity Scale measure: Change in Parkinson's Fatigue Scale measure: Change in Parkinson's Disease Questionnaire 39 measure: Change in Baecke Habitual Physical Activity Questionnaire measure: Change in Pitchburg Sleep Quality Index measure: Change in Major Depression Inventory measure: Change in European Quality of life - 5 Dimensions measure: Change in Non-motor Symptoms Questionnaire measure: Change in Brief Pain Inventory (Short Form) measure: Change in The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale measure: Change in Six Minute Walk Test measure: Change in Timed Up and Go measure: Change in Six Spot Step Test measure: Change in Symbol Digit Modalities Test measure: Change in Montreal Cognitive Assessment measure: Change in Muscle strength measure: Change in aerobic capacity measure: Change in Physical activity measure: Change in Rochester Fatigue Diary measure: Change in Visual Analog Scale for fatigue, tremor, bradykinesia, rigidity and postural instability sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Exercise Biology, Dep. of Public Health, Aarhus University city: Aarhus state: Midtjylland zip: 8000 country: Denmark name: Cecilie Thrue, PhD student role: CONTACT phone: 004520768102 email: ceth@ph.au.dk name: Cecilie Thrue, PhD student role: PRINCIPAL_INVESTIGATOR lat: 56.15674 lon: 10.21076 hasResults: False
nctId: NCT06324409 id: H-350 briefTitle: ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening overallStatus: NOT_YET_RECRUITING date: 2024-03-22 date: 2024-12-31 date: 2025-03-30 date: 2024-03-22 date: 2024-03-25 name: Norwegian Institute of Public Health class: OTHER_GOV briefSummary: The goal of this randomized trial is to test the effect of a reminder telephone call in the official native language in the country where the invitee is born, in addition to the reminder letter in Norwegian on participation in the National Colorectal Cancer Screening Program in Pakistani and Somalian immigrants, compared to the reminder letter in Norwegian only.
The researchers will compare differences in the participation rate in the National Colorectal Cancer Screening Program between the intervention and comparison groups. conditions: Cancer Colorectal studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: There is an intervention group and a comparison group in the study. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 600 type: ESTIMATED name: Reminder telephone call measure: First round screening participation measure: Overall screening participation sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06324396 id: STUDY00002974 briefTitle: IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease acronym: IMPROVE-FALD overallStatus: RECRUITING date: 2024-03-01 date: 2025-12-31 date: 2025-12-31 date: 2024-03-22 date: 2024-03-22 name: Children's Mercy Hospital Kansas City class: OTHER name: Indiana Clinical and Translational Sciences Institute briefSummary: This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation. conditions: Fontan Circulation studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a single center, open-label, prospective, investigation to quantify the effects of liver congestion and fibrosis has on hepatic statin transport (SA1) and response (SA2) in children, adolescents, and young adults with Fontan circulation. primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg) name: Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years) measure: Sildenafil concentration as measured by area under the curve (AUC) measure: Pravastatin concentration as measured by area under the curve (AUC) sex: ALL minimumAge: 8 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Children's Mercy Hospital status: RECRUITING city: Kansas City state: Missouri zip: 64108 country: United States name: Jonathan Wagner, DO role: CONTACT name: Jonathan Wagner, DO role: PRINCIPAL_INVESTIGATOR lat: 39.09973 lon: -94.57857 hasResults: False